Orchestra BioMed (OBIO) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Rezolute (RZLT) over the past year, gaining 97.6% versus a loss of 46.8%. Over five years, RZLT leads with a -30.2% price change compared with -41.8% for OBIO. Rezolute is the larger company by market cap ($472.5 million vs $354.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBIO | RZLT |
|---|---|---|
| Share price | $5.89 | $4.89 |
| Market cap | $354.02M | $472.49M |
| 1-day change | +2.79% | +5.28% |
| YTD return | +38.07% | +96.61% |
| 1-year return | +97.59% | -46.79% |
| 5-year return | -41.83% | -30.23% |
| EPS (TTM) | $-0.86 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.50 | $11.46 |
| 52-week low | $2.86 | $1.07 |
| Distance from 52-week high | -9.38% | -57.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.04% | +100.61% |
| Average volume | 299.84K | 1.50M |
| Shares outstanding | 60.11M | 96.72M |
| Employees | 86 | 58 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed RZLT by 144.4 percentage points over the past year.
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
OBIO vs RZLT FAQ
Which is bigger, Orchestra BioMed or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $472.49M compared with $354.02M for Orchestra BioMed (OBIO).
Which stock has performed better over the past year, OBIO or RZLT?
OBIO returned +97.59% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Orchestra BioMed and Rezolute in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Orchestra BioMed and Biotechnology: Pharmaceutical Preparations for Rezolute.